Constellation Pharmaceuticals
Develops drugs in the field of epigenetics focusing on selective regulators of its function.
| USD | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 3 % | 7 % | (3 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 34 % | 37 % | 38 % | 37 % |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 21 % | 31 % | 42 % | 12 % |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 1 % | 1 % | - |
Source: Company filings or news article
Related Content
Constellation Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development of innovative therapies targeting epigenetic regulators to treat cancer. The company leverages its integrated epigenetics platform to understand the biology of gene expression regulation and develop small molecule product candidates that selectively modulate the activity of these regulators. Constellation Pharmaceuticals primarily serves patients with cancer, aiming to provide new treatment options through its clinical development programs, which are supported by novel biomarker strategies. The company's business model revolves around research and development, clinical trials, and eventual commercialization of its therapeutic candidates. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies.
Keywords: epigenetics, cancer therapy, gene expression, small molecules, clinical trials, biomarkers, biopharmaceutical, oncology, drug development, innovative therapies.